@FierceMedDev: Device maker NeuroMetrix has six months to get its NASDAQ stock price up to the minimum bid. Release | Follow @FierceMedDev
@MarkHFierce: After months of bad defibrillator news, St. Jude hits something better: A CE mark for a neurostim migraine treatment. Story | Follow @MarkHFierce
@DamianFierce: Medtronic is back in court, facing a suit that its pain pump left a man paralyzed. News | Follow @DamianFierce
> More fallout from the 2.3% medical device industry tax slated to begin Jan. 1. Hospitals expect the measure to boost prices and may cut back on purchasing as a result. Story (sub. req.)
> Georgia Tech and Emory University are developing an iPhone app that would diagnose an ear infection at home. Video
> Google Ventures plans a big focus on diagnostics and other life sciences companies as part of its $1 billion in planned investments over the next 5 years. Story
> The medical device research organization NAMSA has opened its newest office in Shanghai. Release
> Intelomed just gained FDA 510(k) clearance for its CVInsight medical device, which measures such things as functional oxygen saturation of arterial hemoglobin and the pulse rate for adult and pediatric patients. Release
> Smiths Medical won 510(k) clearance for a device designed to administer spinal and epidural medication. Release
> Chinese medical devicemaker Dehaier Medical ($DHRM) just secured a three-year procurement deal with a major Ukrainian medical equipment manufacturer. Release
> Researchers in Boston are testing a paper-sized device the size of a postage stamp designed to improve testing for drug-induced liver toxicity in the developing world, MedPage Today reports. Story
Biotech News
@FierceBiotech: In case you missed it yesterday, check out our 2012 Fierce 15 slideshow from BioPharm America 2012. Slideshow | Follow @FierceBiotech
@JohnCFierce: Progenics in Tarrytown gets out the ax (again), cuts research, lops staffers. Release | Follow @JohnCFierce
@RyanMFierce: New pharma-academic tie-up. Bristol-Myers Squibb tapped academics at Vanderbilt on Parkinson's drug research. More | Follow @RyanMFierce
> MorphoSys zeroes in on partner for blockbuster hopeful against arthritis. News
> Vivus: EU regulators expected to balk on obesity drug. Report
> Google VC group eyes biotech bets with $1B purse. Story
Pharma News
@FiercePharma: Philly judge lets J&J CEO Alex Gorsky off the hook; he can't be compelled to testify in Risperdal case. More | Follow @FiercePharma
> Report: Roche's Zelboraf, BMS' Yervoy control their segment. Article
> It's an eye for an eye in EU for Regeneron and Roche. News
> Bayer takes aim at J&J's Evra with new birth control patch. Story
> PhRMA offers help cutting Medicare drug costs, with caveats. More